Hodgkin Lymphoma

Checkpoint Inhibition for Non-Hodgkin and Hodgkin Lymphomas

Checkpoint Inhibition for Non-Hodgkin and Hodgkin Lymphomas

By

Most non-Hodgkin lymphomas do not display the same genetic alteration as classical Hodgkin lymphoma, and are much less susceptible to PD-1 blockade.

PET-driven Therapy Decisions Promising for Hodgkin Lymphoma

PET-driven Therapy Decisions Promising for Hodgkin Lymphoma

By

Patients treated with BEACOPP have improved outcomes compared with ABVD but also face significant adverse events. A major goal of therapy is therefore to minimize toxicity.

Brentuximab Vedotin Plus Bendamustine Safe, Effective as Second-line Hodgkin Lymphoma Treatment

Brentuximab Vedotin Plus Bendamustine Safe, Effective as Second-line Hodgkin Lymphoma Treatment

By

Patients who received the recommended phase 1 dose of brentuximab vedotin and bendamustine had an overall response of 78%.

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, and Dacarbazine Prolongs PFS in Hodgkin Lymphoma

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, and Dacarbazine Prolongs PFS in Hodgkin Lymphoma

By

Researchers randomly assigned 1334 patients with untreated stage III or IV HL to receive A + AVD or ABVD for 6 cycles.

Brentuximab Vedotin Plus Nivolumab May Be Effective Salvage Therapy for Hodgkin Lymphoma

Brentuximab Vedotin Plus Nivolumab May Be Effective Salvage Therapy for Hodgkin Lymphoma

By

Among the 60 evaluable patients, the objective response rate was 83%, with CR rate of 62%.

Nivolumab Provides Long-term Benefit after Auto-HCT Classical Hodgkin Lymphoma

Nivolumab Provides Long-term Benefit after Auto-HCT Classical Hodgkin Lymphoma

By

An interim analysis of a cohort in the CheckMate-205 study showed that nivolumab had an acceptable safety profile and demonstrated efficacy among patients with relapsed and refractory classical Hodgkin lymphoma after post-auto-HCT brentuximab vedotin.

Hodgkin Lymphoma: Assay May Predict Post-transplantation Relapse, Possibly Guiding Non-transplant Options

Hodgkin Lymphoma: Assay May Predict Post-transplantation Relapse, Possibly Guiding Non-transplant Options

By

The gene expression-based prognostic model, RHL30, has the potential to provide insights for the selection of treatment strategies catered to the individual patient.

Hodgkin Lymphoma: Risk-adapted Therapy Recommended

Hodgkin Lymphoma: Risk-adapted Therapy Recommended

By

Long-term follow-up data from randomized trials on Hodgkin lymphoma support current risk-adapted therapeutic approaches for early-stage disease.

Pembrolizumab Effective Regardless of Prior Therapy in Classical Hodgkin Lymphoma

Pembrolizumab Effective Regardless of Prior Therapy in Classical Hodgkin Lymphoma

By

Pembrolizumab treatment resulted in high ORRs among patients with relapsed/refractory classic Hodgkin lymphoma regardless of previous therapy.

Hodgkin Lymphoma Survivors at Risk for Second Cancers

Hodgkin Lymphoma Survivors at Risk for Second Cancers

By

Survivors with a family history of colorectal, breast, and lung cancer were at a significantly higher risk of similar second cancers.

Hodgkin Lymphoma: Nivolumab Active After Allogeneic HCT

Hodgkin Lymphoma: Nivolumab Active After Allogeneic HCT

By

PD-1 blockade with nivolumab was active in patients with Hodgkin lymphoma who received allogeneic hematopoietic cell transplantation.

Hodgkin Lymphoma: Intensifying Treatment With Rituximab After PET

Hodgkin Lymphoma: Intensifying Treatment With Rituximab After PET

By

Adjusting treatment dose after 2 courses of first-line therapy based on a positive PET scan does not improve progression-free survival.

Hodgkin Lymphoma Survivors Treated With Anthracyclines Have 3-fold Risk of Heart Failure

Hodgkin Lymphoma Survivors Treated With Anthracyclines Have 3-fold Risk of Heart Failure

By

Treatment with anthracyclines increases the risk for developing heart failure by 3-fold independently of radiation dose among survivors of Hodgkin lymphoma.

Coping With Waldenstrom Macro-globulinemia

Coping With Waldenstrom Macro-globulinemia

A diagnosis of Waldenstrom's Macroglobulinemia can leave you and your loved ones feeling uncertain, anxious and overwhelmed.

Bendamustine, Gemcitabine, Vinorelbine Promising Treatment for Relapsed or Refractory Hodgkin Lymphoma

Bendamustine, Gemcitabine, Vinorelbine Promising Treatment for Relapsed or Refractory Hodgkin Lymphoma

By

BeGEV appears to provide clinical benefit for patients with relapsed or refractory Hodgkin lymphoma, and ought to be developed further.

Early MRI-based Screening May Reduce Breast Cancer Mortality Among Lymphoma Survivors

Early MRI-based Screening May Reduce Breast Cancer Mortality Among Lymphoma Survivors

By

Early MRI-based screening may reduce breast cancer mortality among women treated with radiotherapy (RT) for childhood Hodgkin lymphoma.

UV Light Exposure May Be Inversely Associated With Hodgkin Lymphoma

UV Light Exposure May Be Inversely Associated With Hodgkin Lymphoma

By

Hodgkin lymphoma incidence was lower in areas of the United States with more ultraviolet radiation exposure.

PET Response-adapted Therapy in Advanced-stage Hodgkin Lymphoma Appears Beneficial

PET Response-adapted Therapy in Advanced-stage Hodgkin Lymphoma Appears Beneficial

By

Patients with advanced-stage Hodgkin lymphoma who were at high risk for treatment failure as determined by interim PET response.

VEPEMB Compared With ABVD for Older Patients With Hodgkin Lymphoma

VEPEMB Compared With ABVD for Older Patients With Hodgkin Lymphoma

By

Standard ABVD was associated with a significant improvement in survival in older patients with Hodgkin lymphoma.

Treatment Disparity Identified in HIV-positive Black Patients With Hodgkin Lymphoma

Treatment Disparity Identified in HIV-positive Black Patients With Hodgkin Lymphoma

By

Significant disparities have been found in HIV-positive black patients with Hodgkin lymphoma, with regard to both rate of diagnosis and chemotherapy usage.

ABVD Shows Higher Progression-free Survival in Hodgkin Lymphoma

ABVD Shows Higher Progression-free Survival in Hodgkin Lymphoma

By

Patients with advanced Hodgkin lymphoma treated with BEACOPP or CEC did not show a progression-free survival.

We Can Treat Hodgkin's Lymphoma Like Melanoma?

We Can Treat Hodgkin's Lymphoma Like Melanoma?

By

Isabel Cunningham, MD, Cancer Therapy Advisor Advisory Board member, weighs in on recent discoveries in the treatment of hematologic cancers.

In Stage 1A Hodgkin Lymphoma, Involved-field Radiotherapy Should Be Standard of Care

In Stage 1A Hodgkin Lymphoma, Involved-field Radiotherapy Should Be Standard of Care

By

Involved-field radiotherapy (IF-RT) should be considered standard of care for stage 1A nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).

Evaluating Evolution of Incidence Rates of Hodgkin Lymphoma Subtypes

Evaluating Evolution of Incidence Rates of Hodgkin Lymphoma Subtypes

Recent declines in nodular sclerosis (NS) rates represented true incidence changes in Hodgkin lymphoma (HL).

Higher Survival with Brentuximab Vedotin After Stem Cell Transplant

Higher Survival with Brentuximab Vedotin After Stem Cell Transplant

For Hodgkin's lymphoma, brentuximab vedotin is associated with improved progression-free survival after autologous stem-cell transplant.

PET-Adapted Salvage Therapy Achieves Negativity in Hodgkin Lymphoma

PET-Adapted Salvage Therapy Achieves Negativity in Hodgkin Lymphoma

PET-adapted sequential salvage therapy with brentuximab could optimize chance of cure in relapsed and refractory Hodgkin lymphoma.

Socioeconomic Factors Affect Treatment Selection, Outcomes in Early-Stage Hodgkin Lymphoma

Socioeconomic Factors Affect Treatment Selection, Outcomes in Early-Stage Hodgkin Lymphoma

Socioeconomic factors affect selection of curative treatments in Hodgkin lymphoma.

ABVD for Early-Stage Hodgkin's Lymphoma Less Effective Without Bleomycin, Dacarbazine

ABVD for Early-Stage Hodgkin's Lymphoma Less Effective Without Bleomycin, Dacarbazine

Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) is the standard of care for early-stage favorable Hodgkin's lymphoma

Brentuximab Vedotin Improves Survival in Hodgkin Lymphoma at Risk for Progression

Brentuximab Vedotin Improves Survival in Hodgkin Lymphoma at Risk for Progression

By

Brentuximab vedotin in Hodgkin lymphoma at risk for progression following autologous stem cell transplantation (ASCT) resulted in better survival.

Nivolumab Highly Effective in Relapsed/Refractory Classical Hodgkin Lymphoma

Nivolumab Highly Effective in Relapsed/Refractory Classical Hodgkin Lymphoma

By

Nivolumab-mediated programmed cell death-1 (PD-1) blockade produced responses in classical Hodgkin lymphoma (cHL).

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs